Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...
As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...
Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2539.30 as on 11 Nov, 2024, 03 ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Showcase your company news with guaranteed exposure both in print and online Most Admired CEOs were built for times like these. Their leadership & actions are guiding the… 25 years ago, Denver's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback